Reversible Posterior Leukoencephalopathy Syndrome Developing After Restart of Sunitinib Therapy for Metastatic Renal Cell Carcinoma

Table 1

Reversible posterior leukoencephalopathy syndrome caused by sunitinib treatment.

Case	Age/gender	Disease	Onset after sunitinib	Sunitinib; dose (mg)	Blood pressure; (mmHg)	Management	Clinical outcome of RPLS
1 [3]	54/F	GIST	8 months	50	210/110	Sunitinib discontinuation; antihypertensive drug; anticonvulsant	Complete recovery in 10 days
2 [3]	70/F	RCC	2 weeks	50	170/100	Complete discontinuation; antihypertensive drug; anticonvulsant	Complete recovery in a few days
3 [3]	81/F	RCC	5 months	—	130/74	Sunitinib discontinuation	Complete recovery in 1 month
4 [4]	84/F	RCC	2 weeks	50	142/72	Sunitinib discontinuation	Complete recovery in 3 days
5 [3]	39/F	RCC	1 week	—	160/102	Sunitinib discontinuation; antihypertensive drug; anticonvulsant	Complete recovery in 2 weeks
6 [3]	48/F	RCC	1 week	50	190/130	Sunitinib discontinuation	Complete recovery in 3 weeks
7 [3]	65/M	RCC	8 days	50	160/100	Sunitinib discontinuation; antihypertensive drug	Complete recovery in 17 days
8 [5]	61/M	RCC	15 weeks	50	202/101	Sunitinib discontinuation; antihypertensive drug; anticonvulsant	Complete recovery in 10 weeks
9 [6]	48/F	RCC	3 months	50	178/117	Sunitinib discontinuation; antihypertensive drug; anticonvulsant	Complete recovery in 8 weeks
10 [7]	71/F	RCC	8 months	37.5	179/110	Sunitinib discontinuation; antihypertensive drug; anticonvulsant	Complete recovery in 3 days
11 [8]	67/M	RCC	2 months	50	180/100	Sunitinib discontinuation; antihypertensive drug; anticonvulsant	Complete recovery not achieved; (cancer death in a few weeks)
Present case	64/M	RCC	2 years; (5 months from reinitiation)	50	230/129	Sunitinib discontinuation; antihypertensive drug; anticonvulsant	Complete recovery in 3 weeks